Agios Pharmaceuticals (AGIO) Scheduled to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect Agios Pharmaceuticals to post earnings of ($1.57) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, topping the consensus estimate of ($1.65) by $0.20. The company had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The firm’s revenue for the quarter was up 46.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.47) earnings per share. On average, analysts expect Agios Pharmaceuticals to post $-2 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Price Performance

AGIO stock traded up $0.34 during midday trading on Tuesday, hitting $47.77. The stock had a trading volume of 35,472 shares, compared to its average volume of 788,005. The business has a 50-day moving average of $43.48 and a two-hundred day moving average of $34.00. Agios Pharmaceuticals has a 52-week low of $19.80 and a 52-week high of $50.35.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on AGIO shares. Royal Bank of Canada increased their target price on Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 4th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. The Goldman Sachs Group increased their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $50.67.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.